dornase alfa


Also found in: Dictionary, Wikipedia.
Related to dornase alfa: Pulmozyme, cystic fibrosis

dornase alfa

 [dor´nāz al´fah]
recombinant human deoxyribonuclease I (DNase I) used to reduce the viscosity of sputum in cystic fibrosis patients; administered by inhalation.

dornase alfa

Pulmozyme

Pharmacologic class: Recombinant human deoxyribonuclease I

Therapeutic class: Cystic fibrosis agent, mucolytic enzyme, respiratory inhalant

Pregnancy risk category B

Action

Selectively cleaves to DNA in sputum, decreasing viscosity of pulmonary secretions

Availability

Inhalation solution: 2.5-mg ampule (1 mg/ml)

Indications and dosages

To reduce respiratory tract infections and improve pulmonary function in patients with cystic fibrosis

Adults and children: One ampule (2.5 mg) inhaled once daily; some patients may benefit from twice-daily dosing. Safety and efficacy of daily administration haven't been demonstrated for longer than 12 months.

Contraindications

• Hypersensitivity to drug, its components, or products derived from Chinese hamster ovary cells

Precautions

Use cautiously in:
• pregnant or breastfeeding patients.

Administration

• Don't shake, dilute, or mix with other drugs.
• Use only with approved nebulizer.
• Discard cloudy or discolored solution.

Adverse reactions

CV: chest pain

EENT: conjunctivitis, rhinitis, pharyngitis, hemoptysis, voice changes

Respiratory: dyspnea, increased sputum, wheezing

Skin: rash, urticaria, pruritus

Other: hypersensitivity reactions

Interactions

None known

Patient monitoring

• Assess patient periodically. Report improvement in dyspnea and sputum clearance.
• Monitor for signs and symptoms of hypersensitivity reaction.

Patient teaching

• Teach patient how to use nebulizer.
• Instruct patient to report rash, hives, and itching.
• As appropriate, review all other significant adverse reactions mentioned above.

dornase alfa

/dor·nase al·fa/ (dor´nāz al´fah) recombinant human deoxyribonuclease I (DNase I) used to reduce the viscosity of sputum in cystic fibrosis.

dornase alfa

(dôr′nās′ ăl′fə, -nāz′)
n.
A genetically engineered enzyme used to hydrolyze the DNA in bronchial mucus, facilitating its expectoration, in the treatment of cystic fibrosis.

dornase alfa

[dôr′nās]
a natural enzyme that depolymerizes DNA molecules. Because as much as 70% of the solid matter of purulent material consists of viscous DNA derived from the nuclei of neutrophils, dornase is used in respiratory therapy of disease such as cystic fibrosis to help break down purulent secretions in the airways. Dornase is produced with recombinant DNA technology in Chinese hamster ovary cells.

dornase alfa

A drug used to remove sticky and tenacious secretions from the air passages of people suffering from CYSTIC FIBROSIS. A brand name is Pulmozyme.

dornase alfa

(dor´nās al´fə),
n brand name: Pulmozyme;
drug class: recombinant human deoxyribonuclease (DNase);
action: reduces sputum viscosity;
uses: cystic fibrosis; reduces incidence of pulmonary infection, improves pulmonary function.
References in periodicals archive ?
Dornase alfa is administered through inhalation, during which minimal systemic absorption occurs.
No formal drug interactions have been studied, but clinical trials have shown that dornase alfa can be used effectively with other CF drugs, including enzyme supplements, antibiotics, vitamins, corticosteroids and bronchodilators.
Dornase Alfa - Dornase alfa reduces extracellular DNA and binding polymers to reduce viscosity.
The improvement in FEV1 was achieved on top of aggressive use of multiple concomitant medications, such as inhaled antibiotics, dornase alfa and oral macrolide antibiotics.
Food and Drug Administration (FDA), including dornase alfa, tobramycin, macrolides and digestive enzymes, will be permitted in the trial.
8 sgb v into finished products containing the active ingredient dornase alfa.
The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, dornase alfa (Pulmozyme(TM)).
Phase 2a clinical trial of the AERx(R) Pulmonary Drug Delivery System for the delivery of dornase alfa to patients with cystic fibrosis (CF).
In the second quarter all patient dosing for the Phase IIa clinical trial was completed for the dornase alfa inhalation solution using the AERx(R) Pulmonary Drug Delivery System.
Phase IIa clinical trial of dornase alfa inhalation solution for the management of cystic fibrosis using Aradigm's proprietary AERx(R) Pulmonary Drug Delivery System.
The increase in expenses for 1999 was driven primarily by the timing of development efforts on the pain management and diabetes management collaborations and the initiation of the project to develop an advanced pulmonary delivery system for Genentech's dornase alfa inhalation solution.
Aradigm is also developing a pulmonary delivery system for Genentech's (NYSE: DNA) recombinant manufactured dornase alfa, a human protein that improves lung function in patients having cystic fibrosis.